Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

9.430 +1.010 (+12.00%)
Streaming Delayed Price Updated: 12:43 PM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Trevi Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Dow Gains Over 100 Points; US Job Openings Increase In April
 
Via Benzinga
Topics Stocks
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses. 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Earnings Preview For Trevi Therapeutics
 
Via Benzinga
Trevi Therapeutics: Q4 Earnings Insights
 
Via Benzinga
Earnings Outlook For Trevi Therapeutics
 
Via Benzinga
Trevi Therapeutics's Earnings: A Preview
 
Via Benzinga
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
Earnings Scheduled For March 18, 2025
 
Via Benzinga
Unusual volume stocks are being observed in Tuesday's session.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported. 
Via Benzinga
Top movers in Monday's pre-market session
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
 
Via Benzinga
Topics Stocks
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
 
Via Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
 
Via Benzinga
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
Trevi Therapeutics' CORAL trial progresses unchanged after a positive SSRE review, with topline results for chronic cough in IPF expected by mid-2025. 
Via Benzinga
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out? 
Via MarketBeat
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024
TRVI stock results show that Trevi Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024
TRVI stock results show that Trevi Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023
TRVI stock results show that Trevi Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 20, 2024
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million. 
Via Benzinga
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.